Drug Patents owned by Astellas
1. Drug name - CRESEMBA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6812238 | ASTELLAS | N-substituted carbamoyloxyalkyl-azolium derivatives |
Oct, 2025
(3 years from now) | |
| CN1185230C | ASTELLAS | N-Substituted Carbamoyl Oxy Alkyl-Pyrrole Derivatives |
Oct, 2020
(1 year, 11 months ago) | |
| CN1387529A | ASTELLAS | N-Substituted Carbamoyl Oxy Alkyl-Pyrrole Derivatives |
Oct, 2020
(1 year, 11 months ago) | |
| EP1280795B1 | ASTELLAS | N-Substituted Carbamoyloxyalkyl-Azolium Derivatives |
Oct, 2020
(1 year, 11 months ago) | |
| EP1280795A2 | ASTELLAS | N-Substituted Carbamoyloxyalkyl-Azolium Derivatives |
Oct, 2020
(1 year, 11 months ago) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10206879 | ASTELLAS | Active ingredient containing stabilised solid forms and method for the production thereof |
Sep, 2027
(4 years from now) | |
| US10603280 | ASTELLAS | Active ingredient containing stabilised solid medicinal forms and methods for the production thereof |
Sep, 2027
(4 years from now) | |
Drugs and Companies using ISAVUCONAZONIUM SULFATE ingredient
Treatment: NA
Dosage: POWDER;INTRAVENOUS
| Strength | Dosage | Availability |
|---|---|---|
| 372MG | POWDER;INTRAVENOUS | Prescription |
2. Drug name - LEXISCAN
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6403567 | ASTELLAS | N-pyrazole A2A adenosine receptor agonists |
Apr, 2022
(5 months ago) | |
| US8106183 | ASTELLAS | Process for preparing an A2A-adenosine receptor agonist and its polymorphs |
Feb, 2027
(4 years from now) | |
| CN101379073A | ASTELLAS | Method For Preparing An A2A-Adenosine Receptor Agonist And Its Polymorphs |
Apr, 2013
(9 years ago) | |
| CN102260311A | ASTELLAS | Method For The Preparation Of A Type 2A Adenosine Receptor Agonist And Its Polymorphs Thing |
Mar, 2015
(7 years ago) | |
| CN1358191A | ASTELLAS | N-Pyrazole A |
Jun, 2020
(2 years ago) | |
| CN1167709C | ASTELLAS | N-Pyrazole A |
Jun, 2020
(2 years ago) | |
| EP1189916B1 | ASTELLAS | N-Pyrazole A 2A Receptor Agonists |
Jun, 2025
(2 years from now) | |
| EP1189916A2 | ASTELLAS | N-Pyrazole A 2A Receptor Agonists |
Jun, 2025
(2 years from now) | |
| EP1989214B8 | ASTELLAS | Process For Preparing An A2A-Adenosine Receptor Agonist And Its Polymorphs |
Feb, 2027
(4 years from now) | |
| EP1989214A1 | ASTELLAS | Process For Preparing An A2A-Adenosine Receptor Agonist And Its Polymorphs |
Feb, 2027
(4 years from now) | |
| EP1989214B1 | ASTELLAS | Process For Preparing An A2A-Adenosine Receptor Agonist And Its Polymorphs |
Feb, 2027
(4 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE47301 | ASTELLAS | Process for preparing an A2A-adenosine receptor agonist and its polymorphs |
Feb, 2027
(4 years from now) | |
| Strength | Dosage | Availability |
|---|---|---|
| 0.4MG/5ML (0.08MG/ML) | SOLUTION;INTRAVENOUS | Prescription |
3. Drug name - VESICARE LS
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9918970 | ASTELLAS | Pharmaceutical composition comprising solifenacin |
May, 2031
(8 years from now) | |
| Strength | Dosage | Availability |
|---|---|---|
| 1MG/ML | SUSPENSION;ORAL | Prescription |
4. Drug name - XOSPATA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8969336 | ASTELLAS | Diamino heterocyclic carboxamide compound |
Jan, 2031
(8 years from now) | |
| CN102421761B | ASTELLAS | Two Heterocyclic Carboxamide Compounds |
May, 2030
(7 years from now) | |
| CN102421761A | ASTELLAS | Diamino Heterocyclic Carboxamide Compound |
May, 2030
(7 years from now) | |
| IN292990B | ASTELLAS | Diamino Heterocyclic Carboxamide Compound |
May, 2030
(7 years from now) | |
| IN201108996P4 | ASTELLAS | Diamino Heterocyclic Carboxamide Compound |
May, 2030
(7 years from now) | |
| EP3009428B1 | ASTELLAS | Diamino Heterocyclic Carboxamide Compound |
May, 2030
(7 years from now) | |
| EP3009428A1 | ASTELLAS | Diamino Heterocyclic Carboxamide Compound |
May, 2030
(7 years from now) | |
| EP2428508A4 | ASTELLAS | Diamino Heterocyclic Carboxamide Compound |
May, 2030
(7 years from now) | |
| EP2428508A1 | ASTELLAS | Diamino Heterocyclic Carboxamide Compound |
May, 2030
(7 years from now) | |
| EP2428508B1 | ASTELLAS | Diamino Heterocyclic Carboxamide Compound |
May, 2030
(7 years from now) | |
| EP2428508B9 | ASTELLAS | Diamino Heterocyclic Carboxamide Compound |
May, 2030
(7 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9487491 | ASTELLAS | Diamino heterocyclic carboxamide compound |
Jul, 2030
(7 years from now) | |
| US10786500 | ASTELLAS | Stable pharmaceutical composition for oral administration |
Jul, 2036
(13 years from now) | |
Drugs and Companies using GILTERITINIB FUMARATE ingredient
Treatment: Treatment of acute myeloid leukemia (aml)
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| EQ 40MG BASE | TABLET;ORAL | Prescription |
5. Drug name - XTANDI
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7709517 | ASTELLAS | Diarylhydantoin compounds |
Aug, 2027
(4 years from now) | |
| CN102584712A | ASTELLAS | Diaryl Hydantoin Compound |
Nov, 2015
(6 years ago) | |
| CN105037273A | ASTELLAS | Diaryl Hydantoin Compound |
Mar, 2026
(3 years from now) | |
| CN101222922B | ASTELLAS | Diaryl Hydantoin Compounds |
Mar, 2026
(3 years from now) | |
| CN105037273B | ASTELLAS | Diaryl Hydantoin Compound |
Mar, 2026
(3 years from now) | |
| CN101222922A | ASTELLAS | Diarylhydantoin Compounds |
Mar, 2026
(3 years from now) | |
| CN101460467B | ASTELLAS | Diarylthiohydantoin Compound |
Mar, 2027
(4 years from now) | |
| CN101460467A | ASTELLAS | Diarylthiohydantoin Compounds |
Mar, 2027
(4 years from now) | |
| CN102755318B | ASTELLAS | Diarylthiohydantoin Compound |
Mar, 2027
(4 years from now) | |
| CN102755318A | ASTELLAS | Diaryl Thiohydantoin Compounds |
Mar, 2027
(4 years from now) | |
| EP2444085A1 | ASTELLAS | Diarylhydantoin Compounds As Androgen Receptor Antagonists For Treatment Of Cancer |
Jun, 2016
(6 years ago) | |
| EP2444085B1 | ASTELLAS | Diarylhydantoin Compounds As Androgen Receptor Antagonists For Treatment Of Cancer |
Jun, 2016
(6 years ago) | |
| EP1893196B1 | ASTELLAS | Diarylhydantoin Compound |
Mar, 2026
(3 years from now) | |
| EP1893196A1 | ASTELLAS | Diarylhydantoin Compound |
Mar, 2026
(3 years from now) | |
| EP1893196A4 | ASTELLAS | Diarylhydantoin Compounds |
Mar, 2026
(3 years from now) | |
| EP1893196B2 | ASTELLAS | Diarylhydantoin Compound |
Mar, 2026
(3 years from now) | |
| EP2656842A3 | ASTELLAS | Androgen Receptor Modulator For The Treatment Of Prostate Cancer And Androgen Receptor-Associated Diseases |
Mar, 2027
(4 years from now) | |
| EP2013187A2 | ASTELLAS | Diarylthiohydantoin Compounds |
Mar, 2027
(4 years from now) | |
| EP2013187B1 | ASTELLAS | Diarylthiohydantoin Compounds |
Mar, 2027
(4 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9126941 | ASTELLAS | Treatment of hyperproliferative disorders with diarylhydantoin compounds |
May, 2026
(3 years from now) | |
| US8183274 | ASTELLAS | Treatment of hyperproliferative disorders with diarylhydantoin compounds |
Aug, 2026
(3 years from now) | |
Drugs and Companies using ENZALUTAMIDE ingredient
Treatment: The treatment of patients with metastatic castration-sensitive prostate cancer; treatment of patients with castration-resistant prostate cancer (crpc); The treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel; the treatment of patients with metastatic castration-resistant prostate cancer (crpc).; the treatment of patients with metastatic castration-sensitive prostate cancer; treatment of patients with castration-resistant prostate cancer (crpc)
Dosage: CAPSULE;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 40MG | CAPSULE;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.